The global development of an anti-HIV agent can maximize the information that is available on the clinical utility and safety of a compound by broadening and diversifying the subject population studied. There is a tendency for viral diversity between different geographical regions, and variation in the management of subjects with HIV, across different regions. The two indinavir clinical endpoint studies illustrate the feasibility of successfully conducting clinical trials with broad geographic diversity. As more new compounds are developed in the future, the complexities inherent in this process will drive the need for a global perspective on HIV drug development.
SantosBRBarcellosNTHealth care systems in transition: Brazil Part II: The current status of AIDS in Brazil. J Pub Health Med.1996;18:296–300.
2.
HammerSMSquiresKEHughesMDA controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med.1997;337:725–733.
3.
SuleimanJLewiDUipDIndinavir (DV) alone and with zidovudine (ZDV) in ZDV-naive patients with 50–250 CD4 cells/mm3: Clinical Efficacy. Presented at the Clinical Microbiology and Infectious Diseases 8th European Congress, May 25–28, 1997, Lausanne, Switzerland. Abstract.
4.
Gazzard B on behalf of the International Coordinating Committee.Further results from European/Australian Delta Trial. Presented at the 3rd Conference on Retroviruses and Opportunistic Infections, January 28 to February 1, 1996, Washington DC, USA. Abstract #LB5a.
5.
HammerSMKatzensteinDAHughesMDGundackerHSchooleyRTHaubrichRHA trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med.1996;335:1081–1090.
